HTT and Huntington disease: Decreased mHTT levels in HD model mouse brain following intracerebroventricular administration of HTT-targeting antisense oligonucleotides (ASOs) were shown to induce correlative mHTT lowering in CSF, validating CSF mHTT quantitation as a pharmacodynamic biomarker for HTT lowering clinical trials (Southwell et al., 2015).